Elesclomol
- Generic Name
- Elesclomol
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N4O2S2
- CAS Number
- 488832-69-5
- Unique Ingredient Identifier
- 6UK191M53P
- Background
Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death. In preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal additional toxicity, at moderate doses. It is being developed by Synta Pharmaceuticals.
- Indication
Investigated for use/treatment in melanoma.
Statins, Cholesterol and Cognitive Decline in Alzheimer's
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 2000
- Registration Number
- NCT06635252
- Locations
- 🇸🇪
Karolinska Institutet, Stockholm, Sweden
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 36
- Registration Number
- NCT01280786
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Conditions
- Ovarian Transitional Cell TumorFallopian Tube Transitional Cell CarcinomaOvarian Seromucinous CarcinomaOvarian Serous AdenocarcinomaOvarian Brenner TumorOvarian Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Undifferentiated CarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid Adenocarcinoma
- Interventions
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- GOG Foundation
- Target Recruit Count
- 58
- Registration Number
- NCT00888615
- Locations
- 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States
🇺🇸Regional Cancer Center at Indian Path Community Hospital, Kingsport, Tennessee, United States
🇺🇸Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States
A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 30
- Registration Number
- NCT00827203
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Maryland, United States
🇺🇸University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development, San Antonio, Texas, United States
🇺🇸University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 34
- Registration Number
- NCT00808418
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Maryland, United States
🇺🇸Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, California, United States
🇺🇸University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 630
- Registration Number
- NCT00522834
- Locations
- 🇺🇸
The Ohio State University., Columbus, Ohio, United States
🇺🇸Cancer Pavilion, Pittsburgh, Pennsylvania, United States
🇺🇸University of California San Diego Moores UCSD Cancer Center, La Jolla, California, United States
A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas
- Conditions
- Soft Tissue Sarcoma
- First Posted Date
- 2004-07-23
- Last Posted Date
- 2006-06-20
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 80
- Registration Number
- NCT00087997
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Palm Beach Cancer Institute, West Palm Beach, Florida, United States
🇨🇦Mount Sinai Hospital, Toronto, Ontario, Canada
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Stage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
- First Posted Date
- 2004-07-21
- Last Posted Date
- 2008-12-04
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 86
- Registration Number
- NCT00088088
- Locations
- 🇺🇸
Cancer Institute Medical Group, Santa Monica, California, United States
🇺🇸Oncology Hematology Consultants, Sarasota, Florida, United States
🇺🇸Overton Brooks, VAMC, Shreveport, Louisiana, United States
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
- Conditions
- Melanoma
- First Posted Date
- 2004-06-10
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 103
- Registration Number
- NCT00084214
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Piedmont Oncology Specialists, Charlotte, North Carolina, United States
🇺🇸James Graham Brown Cancer Center - University Of Louisville, Louisville, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.